A pill called ensitrelvir is the first drug shown to effectively reduce infection after exposure to SARS-CoV-2.

Ensitrelvir has already been approved as a prophylactic in Japan, with an FDA decision in the U.S. expected soon.

An experimental COVID-19 pill developed by Japan's Shionogi cut the risk of infection among people exposed to the disease at ...

The antiviral drug ensitrelvir prevents infection in household contacts of COVID-19 patients when given within 72 hours after ...

Shionogi & Co.'s oral COVID-19 pill in development will likely not be recommended for pregnant women due to abnormalities ...

An antiviral pill has, for the first time, been shown to prevent COVID-19 in people exposed to the SARS-CoV-2 virus at home, according to trial results published today in the New England Journal of ...

Add Yahoo as a preferred source to see more of our stories on Google. The logo of Shionogi & Co Ltd is displayed at their Tokyo branch office in Tokyo TOKYO (Reuters) - Japan's Shionogi & Co said on ...

TOKYO, May 13 (Reuters) - Japan's Shionogi & Co (4507.T), opens new tab said on Monday its pill-based treatment for COVID-19 did not meet the primary endpoint of showing a statistically significant ...

TOKYO, Oct 24 (Reuters) - Japan's Shionogi & Co (4507.T), opens new tab on Monday raised its full-year sales forecast on expectations its oral treatment for COVID-19 will be approved by domestic ...

TOKYO (Reuters) - Japan's Shionogi & Co said on Tuesday a global, late-stage study showed its pill-based treatment for COVID-19 was effective in reducing transmission of the disease. Ensitrelvir, ...